These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23944372)

  • 1. An epidemiological study of neovascular age-related macular degeneration in Germany.
    Krause L; Yousif T; Pohl K;
    Curr Med Res Opin; 2013 Oct; 29(10):1391-7. PubMed ID: 23944372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study.
    Silva R; Cachulo ML; Fonseca P; Bernardes R; Nunes S; Vilhena N; Faria de Abreu JR
    Ophthalmologica; 2011; 226(3):110-8. PubMed ID: 21822000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related macular degeneration in Onitsha, Nigeria.
    Nwosu SN
    Niger J Clin Pract; 2011; 14(3):327-31. PubMed ID: 22037079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial.
    Li B; Powell AM; Hooper PL; Sheidow TG
    JAMA Ophthalmol; 2015 Mar; 133(3):276-82. PubMed ID: 25473945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of optical coherence tomography in diagnosis of age-related macular degeneration. Correlation of fluorescein angiography and OCT findings].
    Spraul CW; Lang GE; Lang GK
    Klin Monbl Augenheilkd; 1998 Mar; 212(3):141-8. PubMed ID: 9592738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents.
    Tomany SC; Wang JJ; Van Leeuwen R; Klein R; Mitchell P; Vingerling JR; Klein BE; Smith W; De Jong PT
    Ophthalmology; 2004 Jul; 111(7):1280-7. PubMed ID: 15234127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of CD200 on circulating CD11b+ monocytes in patients with neovascular age-related macular degeneration.
    Singh A; Falk MK; Hviid TV; Sørensen TL
    Ophthalmology; 2013 May; 120(5):1029-37. PubMed ID: 23410964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients.
    Alexander SL; Linde-Zwirble WT; Werther W; Depperschmidt EE; Wilson LJ; Palanki R; Saroj N; Butterworth SL; Ianchulev T
    Ophthalmology; 2007 Dec; 114(12):2174-8. PubMed ID: 18054636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of aspirin use with age-related macular degeneration.
    Liew G; Mitchell P; Wong TY; Rochtchina E; Wang JJ
    JAMA Intern Med; 2013 Feb; 173(4):258-64. PubMed ID: 23337937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of photographic screening for neovascular age-related macular degeneration.
    Maberley DA; Isbister C; Mackenzie P; Aralar A
    Eye (Lond); 2005 Jun; 19(6):611-6. PubMed ID: 15184945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating omega-3 Fatty acids and neovascular age-related macular degeneration.
    Merle BM; Benlian P; Puche N; Bassols A; Delcourt C; Souied EH;
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):2010-9. PubMed ID: 24557349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL; Yu F
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
    Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
    Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of patients presenting with exudative maculopathy and neovascular retinal disease in an urban population.
    Ergun E; Abramov A; Zawinka C; Stur M
    Wien Klin Wochenschr; 2004 Nov; 116(21-22):737-43. PubMed ID: 15628644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Pruente C
    Prog Retin Eye Res; 2007 Jul; 26(4):437-51. PubMed ID: 17512238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of CXCR3 expression on peripheral blood leukocytes in patients with neovascular age-related macular degeneration.
    Falk MK; Singh A; Faber C; Nissen MH; Hviid T; Sørensen TL
    Invest Ophthalmol Vis Sci; 2014 May; 55(7):4050-6. PubMed ID: 24812555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration.
    Zweifel SA; Imamura Y; Spaide TC; Fujiwara T; Spaide RF
    Ophthalmology; 2010 Sep; 117(9):1775-81. PubMed ID: 20472293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is pseudophakia a risk factor for neovascular age-related macular degeneration?
    Sutter FK; Menghini M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Bosch MM; Helbig H
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1472-5. PubMed ID: 17389473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity.
    Bandello F; Lafuma A; Berdeaux G
    Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):96-103. PubMed ID: 17197522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.